ardiac hypertrophy is a critical pathogenetic process leading to heart failure, with an incidence and prevalence that is rapidly increasing worldwide. The lifetime risk of heart failure is 1 in 5 among both men and women. Cardiac hypertrophy is characterized as proliferation-independent cardiomyocyte growth, which bears some similarity to tumor growth. To date, many oncogenes have been demonstrated to positively regulate cardiac hypertrophy. For example, aberrant activation of Ras (small guanine nucleotide-binding protein) is a step in the development of many types of cancers. 1 Cardiac overexpression of constitutively active Ras manifested ventricular hypertrophy. 2 This evidence indicates that the signaling programs regulating cell proliferation may be closely related to the programs that control growth of postmitotic adult cardiomyocytes.
Clinical Perspective on p 2715
One of these signaling programs, which may be critical in both aberrant growth in cancer and in cardiac hypertrophy, is a cascade involving p21-activated kinase 1 (Pak1). There is provocative evidence for a role in of Pak1 tumor formation, 3, 4 yet its role in cardiac hypertrophy signaling remains largely unexplored. The Pak family is a group of evolutionarily conserved serine/threonine protein kinases consisting of 6 isoforms subdivided into 2 groups. Pak1 belongs to the group I subfamily and was first discovered as a major binding partner for small GTPases Rac1 and Cdc42. 5 When cells face inciting stimuli, Cdc42/Rac1 becomes activated via exchange of GDP for GTP, 6 and activated Cdc42/Rac1 binds to Pak1, which, in turn, induces the activation of Pak1. 7 At the last count, approximately 40 proteins in various cell types have been identified as downstream effectors of Pak1 reflecting the range of its biological activities, including regulation of cell proliferation, cell survival, and cell motility. 8 Pak1 is abundant in the heart. Important findings by us and others lay the groundwork for suggesting the significant physiological roles of this kinase in the heart. 9 -12 In the present study, we aimed to examine our hypothesis that Pak1 may play an important role in cardiac hypertrophy and in the transition to heart failure, and to investigate whether Pak1 is a potential therapeutic target for antihypertrophic treatment.
Using both primary cardiomyocytes and Pak1 cko mice, we discovered that Pak1 acts as a novel signaling hub relaying antihypertrophic and survival signals from small GTPases to the JNK cascade in the heart. Furthermore, we observed that application of FTY720, a sphingosine-like synthetic analog with an ability to activate Pak1, 13, 14 prevented the development of cardiac hypertrophy in load-stressed wild-type mice, and its antihypertrophic effect was likely due to its function to activate Pak1. Overall, these data demonstrate for the first time that Pak1 activation exerts a beneficial effect by resisting stress-induced hypertrophic remodeling, and Pak1 may thus be a potential therapeutic target for antihypertrophic treatment.
Methods
More details are available in the online-only Data Supplement Methods.
Adenoviral Infection of NRCMs
Adenovirus-mediated gene transfection of NRCMs was performed by methods described previously. 15 Adenovirus expressing shPak1 (CTGTTCTGGATGTGTTGGAAT) was generated using the BLOCK-iT adenoviral RNAi expression system (Invitrogen). Adenoviruses expressing caPak1 (constitutively active Pak1) or NFATluciferase reporter gene (Ad-NFAT-Luc) are described elsewhere. 10, 16 Ad-caMKK7 (constitutively active MKK7) was a kind gift from Dr. Hiroki Aoki (Kurume University, Japan). After infection, NRCMs were subjected to immunocytochemistry, quantitative reverse transcriptase polymerase chain reaction (RT-PCR), immunoblot analyses, and luciferase reporter assay to investigate the role of Pak1 in cardiac hypertrophy.
Generation of Pak1
f/f and Pak1 cko Mice
Pak1 genomic DNA was used for constructing a gene-targeting vector with 2 LoxP sites flanking exon 3 of pak1. 129Sv-derived R1 embryonic stem (ES) cell transfection, selection, screening, and blastocyst injection were performed as described previously. 17 Germline-transmitting chimeras were generated and mated with C57BL/6 females to produce heterozygous Pak1 flox mice, which were back-crossed into a C57BL/6 background for 5 generations to obtain homozygous Pak1 flox (Pak1 f/f ) mice. To generate Pak1 cko mice, Pak1 f/f mice were mated with mice expressing Cre under ␣-myosin heavy chain (␣MHC) promoter (␣MHC-Cre). 18 Quantitative RT-PCR, immunoblotting, and immunostaining were used to verify Pak1 deletion. All mice used in this study were maintained in a pathogen-free facility at the University of Manchester. The animal studies were performed in accordance with the UK Home Office and institutional guidelines.
Hypertrophy Models and FTY720 Administration
Cardiac hypertrophy was induced by administration of angiotensin II (Ang II, Sigma-Aldrich) at 1 g ⅐ g -1 ⅐ d -1 for 14 days via osmotic mini-pumps (Alzet) implanted subcutaneously in 8-to 10-week-old male Pak1 cko mice and their littermates (Pak1 f/f mice), or by transverse aortic constriction (TAC) as previously described. 15, 16, 19 For FTY720 (2-amino-2-[2-(4-octylphenyl) ethyl]-1,3-propanediol hydrochloride) administration, on the second day after the operation, TAC-or shamoperated wild-type mice or Pak1 cko mice (C57BL/6 background, 8-to 10-week-old male) were randomized into different groups for intraperitoneal injection of FTY720 (10
, Cayman Chemical) or vehicle (saline) for 5 days. FTY720-LD 50 (50% lethal dose) is 300 g/g. Seven days after the operation (5 days post FTY720 injection), hearts were taken from different experimental groups, and the hypertrophic responses were analyzed by histology, quantitative RT-PCR, echocardiography, and hemodynamic analysis.
Data Analysis
Two-way ANOVA followed by Bonferonni corrected post hoc t test was used for comparisons among multiple groups. Comparisons between 2 groups were performed using Student t test. Probability values Ͻ0.05 are considered statistically significant. Data are expressed as meanϮSEM. Where sample sizes were Ͻ5, tests were also conducted using ranked data. In all cases, statistical conclusions were the same. For simplicity we present only the parametric results. Figure 1A ). Pak1 phosphorylation was also appreciably increased in ventricular tissues of wild-type mice subjected to TAC for 2 weeks ( Figure 1A ). We next assessed whether Pak1 exerts a prohypertrophic or an antihypertrophic effect in response to hypertrophic stimuli in NRCMs. NRCMs were infected with the Ad-caPak1 (constitutively active Pak1) or control adenovirus Ad-GFP 48 hours before PE treatment. Unexpectedly, Ad-caPak1 abrogated the prohypertrophic effect of PE, showing a significantly smaller cell surface area concomitant with a nearly 2-fold downregulation of ANP mRNA expression ( Figure 1B and 1C) . Furthermore, we examined whether activated Pak1 affects NFAT transcriptional activity, which plays a central role in regulating cardiac hypertrophy. In line with results reported above, adenoviral infection of the NFAT-luciferase reporter (Ad-NFAT-Luc) in control NRCMs (infected with Ad-LacZ) led to enhanced NFAT reporter activity after PE stimulation. However, infection of Ad-caPak1 did not lead to any increase in NFAT activity despite PE stimulation ( Figure 1D ).
Results

Pak1
To corroborate these data, we adopted a gene knockdown system in NRCMs, in which Pak1 expression was deleted by 85% after infection with Ad-shPak1; expression of Pak2 and Pak3 (close Pak family isoforms) remained unchanged (Figure 2A) . Compared with NRCMs infected with scrambled shRNA (Ad-shC2), PE induced significantly greater increases in cell size and in ANP mRNA level in NRCMs infected with Ad-shPak1 ( Figure 2B and 2C) .
To investigate the potential mechanism whereby Pak1 deficiency promoted hypertrophy, we screened a range of hypertrophic regulators. Our data demonstrate a prominent defect in JNK phosphorylation in shPak1-infected NRCMs after PE stimulation ( Figure 2D ). Furthermore, MKK4 and MKK7 (upstream activators of JNK) were found not to respond to PE stimulation in the absence of Pak1 ( Figure 2D ). However, phosphorylation levels of MEKK1, p38, ERK1/2, and PKB were similar in the two groups following PE treatment ( Figure 2D) .
Finally, NFAT transcriptional activity was examined when Pak1 was knocked down. We discovered that PE stimulation of shPak1-infected NRCMs resulted in enhanced NFAT activity. However, this increase in NFAT activity was mitigated by infection with constitutively active MKK7 (Ad-caMKK7), indicating that loss of Pak1 induces greater cardiomyocyte hypertrophy by promoting increased NFAT activity, which is likely to occur via the JNK pathway ( Figure 2E ).
Generation and Characterization of Cardiomyocyte-Specific Pak1 Knockout Mice
Prompted by our results showing that Pak1 might be a critical signaling nexus limiting hypertrophy, we moved on to studies addressing our hypothesis in the intact heart. To precisely ascertain the in vivo role of Pak1 in the heart, we generated cardiomyocyte-specific Pak1 deletion mice (Pak1 cko ). Mice with a germline modification in the pak1 gene with 2 LoxP elements flanking exon 3 (Pak1 f/f ) were generated (onlineonly Data Supplement Figure IA and IB). Pak1 f/f mice were healthy and fertile, indicating that the presence of two LoxP sites did not affect Pak1 function in vivo.
To establish Pak1 cko mice, Pak1 f/f mice were bred with ␣MHC-Cre mice. Pak1 cko mice developed to term and were viable and fertile in adulthood. PCR amplification of genomic DNA prepared from cardiomyocytes, brain, liver, and skeletal muscle of 8-week-old Pak1 f/f and Pak1 cko mice confirmed the specific recombination of the pak1 gene in cardiomyocytes (online-only Data Supplement Figure IIA) . The deletion of the pak1 gene product in cardiomyocytes was verified at mRNA and protein levels (online-only Data Supplement Figure IIB through IID) . Notably, loss of Pak1 in cardiomyocytes did not induce any compensatory changes in the protein levels of its activators, Cdc42 and Rac1, as well as its close family members Pak2 and Pak3, and potential effectors, such as ERK1/2, JNK, and p38 (online-only Data Supplement Figure IID and IIE).
Disruption of Pak1 in Cardiomyocytes Exacerbates Pressure Overload-Induced Hypertrophy
We next determined whether Pak1 is involved in regulating cardiac hypertrophy. Pressure overload by TAC was applied to 8-week-old Pak1 f/f and Pak1 cko mice. Following 2 weeks of TAC, Pak1 f/f mice developed a moderate 19% increase in heart weight/tibia length (HW/TL) ratio, whereas Pak1 cko mice showed a 53% increase in HW/TL ratio ( Figure 3A) . Consistent with this result, there was a significant increase in the cross-sectional area of Pak1 cko -TAC cardiomyocytes (338.7Ϯ2.74 m 2 ) compared with Pak1 f/f -TAC cardiomyocytes (242.43Ϯ4.54 m 2 ) ( Figure 3B ). Sirius Red staining to determine collagen deposition (Figure 3C ) showed more interstitial fibrosis in Pak1 cko -TAC myocardium (6.1% fibrotic area compared with 1.6% in the controls). Loss of Pak1 also induced cardiomyocyte apoptosis, indicated by a 5-fold increase in the number of TUNEL-positive nuclei in Pak1 cko -TAC myocardium compared with Pak1 f/f hearts ( Figure 3D ). Reactivation of the fetal gene program was measured by quantitative RT-PCR; expression of ANP, brain natriuretic peptide (BNP), and ␤-myosin heavy polypeptide (Myh7) mRNA was significantly elevated in the hypertrophied Pak1 cko myocardium ( Figure 3E ). Regulator of calcineurin 1 variant 4 (RCAN1.4) is a target gene of NFAT transcription factors. Increased RCAN1.4 mRNA expression was detected in TAC-stressed Pak1 cko hearts, indicating enhanced NFAT signaling in the knockout mice ( Figure 3E ). Moreover, as illustrated in Figure 3E , mRNA levels of procollagen type I, ␣2 (Col1␣2), and procollagen type III, ␣1 (Col3␣1) were markedly upregulated in the Pak1 cko myocardium. Although greater hypertrophy and salient remodeling occurred in the Pak1 cko -TAC mice, their contractile performance remained normal, as indicated by similar fractional shortening between the 2 groups after TAC (online-only Data Supplement Table I ). Thus, we conclude that ablation of Pak1 in cardiomyocytes promotes hypertrophic remodeling in response to TAC stress.
Prolonged Load Stress Sensitizes Pak1 cko Mice to Heart Failure
To further determine whether loss of Pak1 in cardiomyocytes predisposes mice to heart failure, we extended the TAC stress imposed on Pak1 f/f and Pak1 cko mice to 5 weeks. Indeed, Pak1 cko mice showed characteristics of heart failure after TAC. Lung weight to tibia length (LW/TL) ratio was substantially higher in Pak1 cko -TAC mice, indicating pulmonary edema due to contractile insufficiency ( Figure 4A) . A significant reduction in FS (19.89Ϯ1.8%) in the knockouts confirmed heart failure, whereas Pak1 f/f mice exhibited preserved contractility ( Figure 4B ). The increases in HW/TL ratio (83%) and in the myocyte cross-sectional area (419.83Ϯ2.0 m 2 ) became even more prominent in Pak1 cko mice after prolonged TAC stress ( Figure 4C and 4D ). In addition, increased collagen deposition (9.1%) was scattered over the working myocardium of Pak1 cko -TAC mice ( Figure 4E ). These results demonstrated that mice were more vulnerable to longer pressure overload stress and more readily made the transition into heart failure when Pak1 was absent. Figure IIIC) . We measured ROS production by DHE staining; there were no significant differences detected between the two genotypes (online-only Data Supplement Figure IIID) . Also, cardiac function in Pak1 cko mice was comparable to that in the control group (online-only Data Supplement Figure IIIE) . Together, these results illustrate that Pak1 antagonizes cardiac hypertrophy not only by mechanical stress-induced membrane receptor activation, but also by neuroendocrine agonist stimulation.
Enhanced Hypertrophic Remodeling Is Induced in
The JNK Cascade Acts Downstream of Pak1 in Cardiac Hypertrophic Remodeling
To obtain in vivo evidence of the regulatory mechanism whereby Pak1 modulates hypertrophic responses, we surveyed downstream candidates. Consistent with data that we obtained from NRCMs, TAC treatment did not induce the activation of MKK4/MKK7-JNK pathway in the Pak1 cko myocardium, whereas activation of p38, ERK1/2, and PKB, as well as PP2A activity (phosphorylation of Y307), remained the same between the 2 groups ( Figure 5A ).
We also examined apoptotic molecules that might be responsible for the higher rate of cardiomyocyte death in the knockout hearts. Interestingly, we found augmented protein levels of p53, Bax, and Bad in the Pak1 cko -TAC myocardium. However, there were no significant differences observed in either the expression of Bim and Bcl-2, or phosphorylation of Bad at Ser 112 ( Figure 5B ), which is a known site for Pak1-mediated phosphorylation. 20 Thus, these data demonstrate that the MKK4/MKK7-JNK pathway acts downstream of Pak1 in protecting the heart from hypertrophic stress.
FTY720 Induces Pak1 Activation and Prevents Cardiac Hypertrophy
Led by the results above, we tested whether Pak1 is a potential therapeutic target for antihypertrophic treatment. First, we demonstrated that FTY720 was able to induce Pak1 phosphorylation in NRCMs and in wild-type mouse myocardium ( Figure 6A ). Then, we discovered that treatment of NRCMs with FTY720 (200 nmol/L, 48 hours) significantly reduced PE-induced hypertrophic responses, indicated by a significantly smaller cell surface area together with markedly decreased ANP expression ( Figure  6B ). Interestingly, Pak1-knockdown NRCMs treated with or without FTY720 showed no significant differences in PE-induced increases in cell surface area and ANP expression ( Figure 6B ), suggesting FTY720 likely functions via Pak1 activation to block hypertrophic responses. It is noteworthy that, using trypan blue staining to check cell viability, we found that FTY720 at a dose of 200 nmol/L was sufficient to restrain hypertrophic responses but did not exhibit a toxic effect on NRCMs ( Figure 6C ), indicating FTY720 may be a suitable agent for antihypertrophic therapy in vivo.
To test this hypothesis, we applied FTY720 (10 g ⅐ g -1 ⅐ d (Figure 7A and 7B). Accordingly, echocardiography also demonstrated that cardiac structure and function of the FTY720-treated TAC mice were similar to the sham groups ( Figure 7C and 7D) . In contrast to the FTY720-treated TAC mice, the TAC mice treated with vehicle developed hypertrophy ( Figure 7A through 7D). Consistent with in vitro data, FTY720 used in this protocol did not exhibit cardiac toxicity in the mice, as FS, dP/dt max (contractile response), and dP/dt min (lusitropic response) in the FTY720-treated groups remained normal compared with the vehicle treated groups ( Figure  7E and 7F) .
Next, we determined whether the antihypertrophic effect of FTY720 was due to Pak1 activation; therefore, the same FTY720 treatment protocol was applied to Pak1 cko mice subjected to either TAC or sham operation. Interestingly, despite FTY720 treatment, TAC was still able to induce hypertrophy in the hearts of Figure 8A and 8B) .
Echocardiography and hemodynamic analysis demonstrated comparable cardiac structure and function between the FTY720-treated TAC mice and the sham groups ( Figure 8C through 8F). Together, these data suggest that the activation of Pak1 by FTY720 is able to prevent the development of cardiac hypertrophy.
Discussion
With the use of cultured rat cardiomyocytes and Pak1 cko mice, we have identified a novel cardioprotective role of Pak1 in attenuating cardiac hypertrophy and halting the transition to heart failure. The major findings of this study are: (1) Pak1 is activated by both mechanical stress and neuroendocrine agonists in the heart; (2) Pak1 is an indispensable upstream activator for the JNK pathway in cko hearts were examined by immunoblotting for total JNK, MKK4, MKK7, p38, ERK1/2, PKB ,and PP2A expression, as well as their phosphorylation levels. The ratios of P/T JNK, P/T MKK4, P/T MKK7, and P/T PP2A are represented by the bar graphs. B, Immunoblot analyses of protein levels of p53, Bax, Bad, Bim, and Bcl-2, as well as phosphorylated Bad. GAPDH expression is the protein loading control. The ratios of p53/GAPDH, Bax/Bcl-2, and Bad/ Bcl-2 are represented by the bar graphs (nϭ6 mice per group).
response to hypertrophic challenges; (3) Pak1 plays a critical role in antagonizing cardiac hypertrophy because hearts of Pak1 cko mice are vulnerable to cardiac hypertrophy and readily progress to failure with application of sustained pressure overload; 4) the activation of Pak1 by FTY720 is able to prevent the development of cardiac hypertrophy, suggesting Pak1 may be a potentially important therapeutic target for antihypertrophic treatment. 
Pak1 Is an Anti-Hypertrophic Regulator in the Heart
This study, for the first time, demonstrates a differing role for Pak1 in cardiomyocyte growth. During the past decade, growing evidence has suggested that Pak1 activation is frequently associated with cell proliferation, survival of cancer cells, and increased invasiveness. In fact, more than half of human breast cancers exhibit hyperactivation or overexpression of Pak1. 21 In cancers, Pak1 activation is inextricably linked with aberrant Ras/Raf/ERK signaling. 8 In the heart, mature cardiomyocytes are terminally differentiated; growth signals do not lead to proliferation, but rather to hypertrophy, which explains why many oncogenes display prohypertrophic effects in the adult heart. 22,23 Thus, we Figure 7 . FTY720 treatment prevented the induction of cardiac hypertrophy in the wild-type transverse aortic constriction (TAC) hearts, demonstrated by significant decreases in (A) heart weight to tibia length (HW/TL) ratio and in (B) mean cross-sectional areas, compared with vehicle-treated TAC-hearts. Echocardiography showed (C) increased ventricular posterior wall thickness (dPW) and (D) interventricular septal wall thickness (dIVS) in vehicle-treated TAC mice, but not in FTY720-treated TAC mice. Fractional shortening (FS %) (E) and in vivo (F) hemodynamic analysis (dP/dt max -contractile response and dP/dt min -lusitropic response) demonstrated that cardiac functions were preserved in FTY720-treated groups (nϭ5-8 mice per group). *Pϭ0.02, #Pϭ0.01 versus vehicle-treated sham-mice.
predicted that Pak1 may exert a function similar to that of the Ras pathway in facilitating cardiac hypertrophy. However, to our surprise, our studies revealed the antihypertrophic property of Pak1 in the heart.
The initiation of cardiac hypertrophy involves neuroendocrine factors, such as angiotensin II, endothelin-1, and phenylephrine, all of which act on G-protein-coupled receptors (GPCRs), in turn; these receptors stimulate heterotrimeric G-proteins such as G q/11 , G 12/13 , and G i for signal transduction. 24 -26 However, small GTPases do not bind with GPCRs, but become activated through exchange of GDP for GTP. The dynamic GTP-binding and GDP-hydrolysis cycle of small GTPases is tightly regulated by GTPase activating proteins (GAPs) and guanine nucleotide exchange factors (GEFs), which cko -transverse aortic constriction (TAC) mice. Heart weight to tibia length (HW/TL) ratio (A) and mean cross-sectional areas (B) showed no difference between vehicle-and FTY720-treated Pak1 cko -TAC mice, although TAC induced increased hypertrophy in both groups, compared with sham groups. Echocardiographic parameters of (C) ventricular posterior wall thickness (dPW) and (D) interventricular septal wall thickness (dIVS) are comparable between vehicleand FTY720-treated Pak1 cko TAC mice. fractional shortening (FS%) (E) and dP/dt max and dP/dt min (F) show normal cardiac functions in FTY720-treated Pak1 cko -TAC mice (nϭ4 -6 mice per group). *Pϭ0.03, # Pϭ0.04 versus vehicle-treated sham mice.
are downstream effectors of heterotrimeric G-proteins. 6, 27 Pressure overload is a potent hypertrophic inducer in the heart. It not only induces the release of neuroendocrine factors to stimulate GPCRs, but also activates stretch sensors or receptor tyrosine kinases for the development of cardiac hypertrophy. 28 When the heart is exposed to various hypertrophic stimuli, prohypertrophic and antihypertrophic signaling pathways are concurrently activated to regulate the hypertrophic process. We discovered that Pak1 was activated by a number of neuroendocrine factor and by pressure overload to antagonize cardiac hypertrophy.
The Cdc42-Pak1-JNK Axis Is a Critical Pathway Relaying Antihypertrophic Signals
Results of studies investigating the role of Cdc42, a key regulator of Pak1 activation, in hypertrophic signaling are consistent with our findings. Maillet et al 29 reported that diverse hypertrophic stimuli increased the activated GTPbound form of Cdc42. Loss of Cdc42 in cardiomyocytes rendered mice more capable of cardiac hypertrophic growth, and Cdc42 is required for JNK activation in response to hypertrophic stress. Their data agree with previous investigations in mammalian cells showing that Cdc42 induces JNK activation. 30 -32 Interestingly, Maillet et al also showed that Cdc42 deficiency in NRCMs led to blunted phosphorylation of MEKK1. MEKK1 is a MAP3K, which preferentially activates the JNK pathway through MKK4 and MKK7, and regulates the activity of the ERK cascade. 33, 34 However, we did not observe altered MEKK1 phosphorylation due to Pak1 deficiency, whereas blunted activation of the MKK4/MKK7-JNK pathway and increased NFAT activity were detected when Pak1 was scarce. MKK4 and MKK7 are upstream kinases for JNKs, which are implicated in the progression of heart failure. 35, 36 JNKs have been shown to antagonize cardiac hypertrophy through inhibition of NFAT activity. 37 Our recent studies using mice with cardiomyocyte-specific deletion of MKK4 or MKK7 support this mechanism. 16, 19 Considering the above evidence, we believe that Pak1 acts upstream of the JNK pathway in hypertrophic signaling, and MEKK1 might not be a direct effector downstream of Pak1-mediated antihypertrophic signaling. It is interesting to note that a recent study by Higuchi et al 38 described a novel property of Pak1; it not only has catalytic function, but can also act as a scaffolding protein for priming Akt activation. Whether Pak1 is able to directly phosphorylate MKK4/MKK7 or aid recruitment of MKK4/MKK7 to specific MAP3Ks in response to hypertrophic stimuli thus remains to be determined.
Our previous study has shown that Pak1 is involved in modulating cardiac contractility through PP2A-mediated dephosphorylation of cardiac troponin I (cTnI). 10 It was proposed that p38 seemed to be an intermediate for Pak1-mediated PP2A activity. 10 As such, we examined p38 activation and PP2A phosphorylation of Y307 (indicating the catalytic activity of PP2A); however, no alteration in p38 activation or PP2A activity was observed in our experimental setting due to Pak1 deficiency in cardiomyocytes under TAC stress. These results suggest that, at least in the model we employed, PP2A or p38 is unlikely to be downstream of Pak1 and responsible for the development of cardiac hypertrophy.
Current knowledge of Cdc42 and Rac1, both of which activate Pak1, suggests differing roles for these small G-proteins in hypertrophic signaling in the heart. In contrast to the promotion of cardiac hypertrophy by downregulation of Cdc42, 29 downregulation of Rac1 inhibits the development of cardiac hypertrophy in response to Ang II infusion via decreased activity of NADPH. 39 Subsequent studies by Custodis et al 40 indicated that Rac1 binding to Rho guanine dissociation inhibitor-␣ may be a mechanism by which Rac1 mediates hypertrophy in a mouse pressure overload model. Rac1 overexpression in myocardium induced hypertrophy in juvenile transgenic mice concurrent with altered intracellular distribution of Pak from the cytosol to cytoskeletal fraction. 41 Yet, in this study by Sussman et al, 41 no information was provided as to which isoform of Pak was involved in the translocation. It is known that other Pak isoforms, such as Pak2 and Pak3, which share substantial sequence homology with Pak1, 42 are also expressed in cardiomyocytes. We have demonstrated that Pak1 cko mice exhibited greater hypertrophy with no increase in ROS production after 2 weeks of Ang II infusion, which is in stark contrast to phenotypes reported in Rac1 cardiomyocyte-specific knockouts. 39 Taking this evidence into account, it is plausible that Pak1 is a primary effector of Cdc42 rather than Rac1. Pak1 is an indispensible component of the Cdc42-Pak1-JNK axis serving as a critical antihypertrophic regulatory pathway.
Pak1 Activation by FTY720 Exerts a Beneficial Effect for Restraining Cardiac Hypertrophy
FTY720 is a sphingosine-like analog approved by the Food and Drug Administration for treating relapsing multiple sclerosis. We have previously reported that FTY720 prevents arrhythmias in an ex vivo rat heart subjected to ischemia/ reperfusion injury. 14 In the ischemia/reperfusion model, Pak1 activation was suggested to be involved in an FTY720-induced protective effect. 14 Our test to determine whether FTY720 activation of Pak1 extended to the induction of cardiac hypertrophy demonstrated that administration of a pharmacological dose of FTY720 (10 g ⅐ g -1 ⅐ d -1 ) was sufficient and effective to limit TAC-induced cardiac hypertrophy in wild-type mice. Meanwhile, the observation that FTY720 failed to block increased cardiac hypertrophy in TAC stressed-Pak1 cko mice provides further support that FTY720 induces its antihypertrophic effect through the activation of Pak1.
Cardiac hypertrophy is traditionally regarded as an adaptive response to normalize ventricular wall stress. According to Laplace's law, FTY720 treatment might cause deterioration in cardiac function and chamber dilation in TAC stressed mice due to limited cardiac hypertrophy; however, none of these were observed in our study. Similarly, in response to pressure overload, preserved cardiac function with no or little hypertrophy was reported by a number of investigations, including studies in which NFAT signaling was inhibited. [43] [44] [45] [46] [47] These findings suggest that hypertrophy may not always be a necessary compensatory response; increased wall stress per se does not cause cardiac dysfunction. Therefore, FTY720 treatment could be of clinical interest given its ability to prevent hypertrophy without deteriorating cardiac function. Furthermore, FTY720, which is derived from myriocin, 48 a component of the natural product Isaria sinclairii, represents a nontoxic sphingosinelike derivative with oral bioavailability that may be useful in the treatment and/or prevention of cardiac disorders in highrisk patients.
In conclusion, we have discovered a novel role for Pak1 as a critical signaling hub in cardioprotection that limits excessive hypertrophic remodeling. Pak1 most likely acts downstream of Cdc42 to convey both antihypertrophic and survival signals to the JNK pathway in cardiomyocytes. Our demonstration of prevention of cardiac hypertrophy by administration of FTY720 provides convincing evidence for the identification of Pak1 as a potential therapeutic target for antihypertrophic treatment.
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